The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SCLX | -47.13% | N/A | N/A | -95% |
| S&P | +18.37% | +110.18% | +16.02% | +79% |
Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTlido, a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain, and e GLOPERBA oral solutions, an FDA-approved prophylactic treatment for painful gout flares in adults. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.
An analyst at H.C. Wainwright initiated coverage on the stock.
The company's shares are being dragged down by its soon-to-be-former parent company.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $9.90M | -39.5% |
| Gross Profit | $5.61M | -48.8% |
| Gross Margin | 56.73% | -10.3% |
| Market Cap | $40.95M | -80.0% |
| Market Cap / Employee | $0.36M | 0.0% |
| Employees | 115 | 9.5% |
| Net Income | -$87.80M | -133.6% |
| EBITDA | -$19.40M | -32.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $4.10M | -40.5% |
| Accounts Receivable | $16.77M | -55.9% |
| Inventory | 2.5 | -18.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $4.14M | -86.6% |
| Short Term Debt | $45.23M | -40.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -130.63% | -27.7% |
| Return On Invested Capital | 17.18% | 5.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $7.29M | 223.0% |
| Operating Free Cash Flow | $7.29M | 223.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -0.58 | -0.41 | -0.23 | -0.15 | -85.82% |
| Price to Sales | 2.13 | 1.38 | 1.98 | 1.54 | -66.17% |
| Price to Tangible Book Value | -14.96 | -6.90 | -6.68 | -0.13 | -99.58% |
| Price to Free Cash Flow TTM | 10.06 | 4.03 | 6.28 | 3.24 | -82.96% |
| Enterprise Value to EBITDA | -10.21 | -4.37 | -5.34 | -5.85 | -74.23% |
| Free Cash Flow Yield | 9.9% | 24.8% | 15.9% | 30.8% | 486.81% |
| Total Debt | $101.37M | $44.76M | $48.81M | $49.37M | -53.86% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
